RealTime Dynamix™: Atopic Dermatitis US Q4 2018 Spotlight
Sanofi/Regeneron’s Dupixent continues to flourish as the only atopic dermatitis game in town, but US dermatologists identify a gap between current patients and candidates for treatment. After over a year and a half on the market, U.S. dermatologists (n=102) remain extremely pleased with Sanofi / Regeneron’s Dupixent. In Spherix’s fourth quarter update of RealTime Dynamix™: Atopic Dermatitis (US), collaborating dermatologists indicated that the first biologic to treat moderate-to-severe atopic dermatitis has consistently exceeded expectations, and satisfaction with the IL-4/13 inhibitor remains extremely high. View complimentary highlights from the most recent update of the quarterly series below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.